← ANALYST RATINGS · TIPRANKS
C4 Therapeutics (CCCC): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $9.00, the highest $10.00, the lowest $7.00. The average is +225.5% from the last price of $2.77.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | −9.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | −9.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $2.50−28.6% | Hold | −9.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Sell | −9.6% | Downgrade | 15.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | −9.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $2.50−28.6% | Hold | −9.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $10.00 | Buy | +261.7% | Initiated | 09.10.26on TipRanks 05:30 | +10.3%next day −3.1% · 5 days −10.5% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $3.50+16.7% | Hold | +26.6% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 | Sell | +8.5% | Downgrade | 01.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $3.50+16.7% | Hold | +26.6% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +8.5% | Reiterated | 25.09.26on TipRanks 05:06 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $10.00 | Buy | +261.7% | Assigned | 12.08.26on TipRanks 06:55 | +0.5%next day +3.9% · 5 days +8.4% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $7.00 | Buy | +153.2% | Reiterated | 12.08.26on TipRanks 05:15 | +0.5%next day +3.9% · 5 days +8.4% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 01:20 | +7.2%next day +0.5% · 5 days +8.4% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $14.00 | Buy | +406.3% | Reiterated | 30.04.26on TipRanks May 29 12:11 | +9.6%next day +2.9% · 5 days +3.5% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $7.00 | Buy | +153.2% | Reiterated | 26.02.26on TipRanks Feb 27 07:30 | +0.9%next day −2.4% · 5 days +10.2% | ↗ |
| Leah R. Cann★★★★★★★★★★#11464 · hits 38% · avg −2.6% | Brookline Capital Markets | $20.00 → $30.00+50.0% | Buy | +985.0% | Reiterated | 23.02.26on TipRanks Feb 24 09:10 | +7.5%next day +3.2% · 5 days +37.2% | ↗ |
| Unknown Analyst | Evercore ISI | $7.00 | Buy | +153.2% | Reiterated | 18.12.25on TipRanks 11:00 | −2.7%next day +0.1% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering C4 Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.50 at a price of $3.33 (+155.3%); now: $9.00 at $2.77 (+225.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 7 | 5 | 5 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.25 to $-0.11). Last quarter: $-0.18.
Sales
Next quarter’s sales estimate — $9M (from $0M to $25M). Last quarter: $7M.
Best top-analyst consensus in the sector · Healthcare
About C4 Therapeutics
- CEO: Andrew J. Hirsch
- Employees: 104
- 490 Arsenal Way, Watertown, MA, 02472, US
- www.c4therapeutics.com
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 173 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗